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Introduction
Increasing adoption of prostate-specific antigen (PSA) testing has led to a migration in the stage and grade of prostate cancer (PCa) at diagnosis such that most affected men present with localised disease [1] . While most patients with clinically localised disease undergo radical prostatectomy (RP) or radiotherapy (RT), local or distant recurrences develop in up to half of intermediate-or high-risk patients within 10 yr [2] .
Elevated or rising PSA level after radical therapy is indicative of recurrent or residual PCa. This biochemical recurrence typically predates clinically detectable metastatic disease by several years [3] . European Association of Urology (EAU) guidelines recommend watchful waiting with possible delayed androgen-deprivation therapy (ADT), or salvage RT, in patients with presumed local failure after RP [2] . A similar approach is recommended for patients with presumed local failure after RT. Nevertheless, the management of these patients is complex and controversial [4] .
The Avodart After Radical Therapy for Prostate Cancer Study (ARTS) assessed the effect of dutasteride (Avodart; GlaxoSmithKline plc, Brentford, Middlesex, UK) on PCa progression in patients with biochemical failure after radical therapy [4] . In this paper, we report the key efficacy and safety findings from the study.
Patients and methods
This was a 2-yr, multicentre, randomised, double-blind, placebocontrolled trial. Eligible men were <85 yr of age with asymptomatic PSA failure following radical therapy with curative intent for clinically localised PCa. Definitions of PSA failure were based on the recommendations from the EAU guidelines on PCa (for subjects treated with RP) or from the Radiation Therapy Oncology Group-American Society for Therapeutic Radiology and Oncology 2005 Consensus Conference (for subjects treated with RT) [2, 5] . Additional entry criteria included serum PSA levels of 2-20 ng/ml for men treated with primary RT or 0.4-10 ng/ml for men treated with RP with or without salvage RT; PSA doubling time (PSADT) >3 mo and 24 mo; clinical stage T1-T3a N0 M0; nonmetastatic PCa as confirmed on negative bone scan within 6 mo prior to randomisation; no evidence of local recurrence in RP or salvage RT subjects; expected survival 2 yr; and Eastern Cooperative Oncology Group performance status 0, 1, or 2. Sixty-four centres in nine European countries (Estonia, France, Finland, Germany, The Netherlands, Russia, Spain, Sweden, and the United Kingdom) randomised at least one subject.
Independent ethics committees approved the protocol and the trial was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice, and any applicable local regulations. All patients provided written informed consent prior to study initiation. The study is registered with ClinicalTrials.gov (NCT00558363).
Randomisation and masking
Eligible subjects were randomised 1:1 to receive dutasteride 0.5 mg or placebo once daily for 2 yr. Randomisation to treatment groups was performed in blocks, stratified by previous therapy (RP with or without salvage RT or primary RT) and by centre. GlaxoSmithKline and site personnel, including participants, were masked to study treatment allocation until the study conduct was finished and the database was frozen.
Outcome measures
The primary efficacy assessment was the number of days between start of treatment and the first instance of PSA value being at least twice the latest PSA value before the start of treatment (baseline), followed by confirmation in the immediate, subsequent PSA evaluation when available. Subjects who did not have PSA doubling were censored at the last postbaseline PSA evaluation. PSA evaluations during the study were performed by a central laboratory.
Secondary efficacy assessments included time to disease progression and the proportion of subjects with disease progression, with time to disease progression defined as the number of days between the start of treatment and the earliest of any of the following: PSADT 3 mo, or PSA >20 ng/ml (subjects who underwent primary RT) or >10 ng/ml (subjects who underwent RP with or without salvage RT) associated with 50% showing a >15% increase from baseline confirmed in all subsequent measurements; time to PSA progression and percentage of subjects with PSA progression based on the definition of a subject experiencing PSADT 3 mo or PSA >20 ng/ml (subjects who underwent primary RT) or PSA >10 ng/ml (subjects who underwent RP with or without salvage RT) associated with 50% increase from the baseline PSA measurement and confirmed in an immediate subsequent PSA level determination. Subjects without PSA rise or PSA progression were censored at the last postbaseline PSA evaluation.
Safety assessments included changes on physical examination, adverse events (AEs), vital signs measurements, and laboratory tests.
All subjects had PSA level monitored every 3 mo during the treatment phase and then at the follow-up visit (4 mo after the end of treatment).
Statistical methods
Given a median time to PSA doubling of 10 to 11 mo for the placebo group [6, 7] and assuming 31.8% of the dutasteride subjects had a PSA doubling at this time point (hazard ratio: 0.605), 110 subjects per treatment arm were required to provide 80% power to show superiority of dutasteride over placebo using a two-sided log-rank test at a = 0.05.
Assuming a 20% withdrawal during the study, approximately 138 subjects per treatment arm were needed to be randomised, for a total of 276 subjects.
The primary population for analysis was the intention-to-treat (ITT)
population, which included all subjects randomised to study treatment.
PSA-related end points considered only the PSA values that might be considered related to the study drug, as restricted by PSA limit date (defined by the latest end-of-treatment visit or laboratory evaluation date and the study drug stop date). PSA evaluations after the PSA limit date were excluded from analysis.
The primary end point was analysed using a log-rank test stratified by previous therapy and investigative-site cluster (defined as a cluster of
countries based on enrolment). The incidence of PSA doubling was compared using a Mantel-Haenszel test, with the analysis repeated and stratified by previous radical therapy, and was also summarised by subgroups of interest (eg, baseline PSADT <12 mo and 12 mo).
The influence of subject characteristics at study baseline or at first PCa diagnosis on time to PSA doubling was assessed using a Cox proportional hazard regression model. Baseline characteristics considered in the model were age, previous radical therapy, time to screening from radical therapy, baseline PSA, and baseline PSADT. Additional factors considered were last PSA value before radical therapy; Gleason score (<7 or 7), T stage (T1c or >T1c), and risk score (low = 0, medium = 1, high = 2) at diagnosis; and hormonal medication use.
Duration of previous hormone therapy (HT) for a subject was calculated from the earliest start and latest stop dates of such therapies: when a date was missing, the 15th of the month was imputed, but if month and/or year were missing, the subject was not used in the calculation of duration of HT.
The proportion of subjects with a treatment response was compared between treatment groups using a Mantel-Haenszel test. Other secondary end points were analysed in a similar way to the primary end point.
AEs and changes in clinical laboratory values were evaluated using the ITT population. Other safety measures included gynaecomastia evaluations every 6 mo, and digital rectal examinations and vital signs measurements every 12 mo. All summaries were provided by randomised treatment group.
Results
Participants
Of the 294 subjects randomised (147 in each treatment group), 187 (64%) completed 24 mo of treatment and 107 discontinued prematurely (71 [48%] in the placebo group, 36 [24%] in the dutasteride group) (Fig. 1 ). The primary reason for discontinuation in both treatment groups was disease progression. Demographics and baseline characteristics were generally similar in the two treatment groups ( 
tumour stage at diagnosis, and use of HT before screening. Using these variables in the model, the RR reduction in favour of dutasteride increased from 66% to 70%, supporting a consistent treatment effect. The RR for PSA doubling was higher for subjects with Gleason score 7 compared with Gleason score <7, and for those with tumour stage >T1c compared with tumour stage T1c. The RR for PSA doubling also increased with higher baseline PSA, lower baseline PSADT, and less time between radical therapy and screening. The RR was lower for primary RT subjects compared with RP subjects and for those who used HT prior to screening compared with those who did not.
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Fig. 2 -Kaplan-Meier estimates of time to prostate-specific antigen doubling (intention-to-treat population). , clinical stage at diagnosis (<T2a, T2b-T2c, or >T2c), and last PSA before radical therapy (<10, 10-20, or >20 ng/ml). Denominators represent the number of data points available when this is not the same as the population. Table 3 presents the incidence of PSA doubling by prespecified subgroups. Among those with baseline PSADT <12 mo, the incidence of PSA doubling was 34% in the dutasteride group and 62% in the placebo group.
Response by previous therapy
The benefit of dutasteride over placebo in delaying the time to PSA doubling was observed both in subjects previously treated with RP ( p < 0.001; RR reduction: 64.65%; 95% CI, 46.64-76.58) and those previously treated with primary RT ( p = 0.007; RR reduction: 73.94%; 95% CI, 25.83-90.84). The incidence of PSA doubling over the 2-yr treatment period was also significantly lower in the dutasteride group than in the placebo group regardless of previous radical therapy (RP: 31% 
Secondary end points
Dutasteride significantly delayed disease progression compared with placebo ( p < 0.001); the overall RR reduction in favour of dutasteride was 59% (95% CI, 32.53-75.09). The Kaplan-Meier curves for time to disease progression began to diverge from approximately month 6, and the divergence between the two treatment groups continued to increase through to month 24 (Fig. 3) . The incidence of disease progression was 17% (25 of 146) in the dutasteride group and 34% (49 of 144) in the placebo group ( p < 0.001). The benefit of dutasteride over placebo for reducing the risk of disease progression was observed across PSA-related disease progression events as well as clinical-related outcomes (Table 4) . Fewer patients in the dutasteride group required additional rescue therapy and fewer developed bone metastases (nine subjects in the placebo group and four in the dutasteride group had bone metastases; five and two of these cases, respectively, were preceded by another disease progression criterion). Forty subjects had at least one intervention for PCa during the study (29 subjects in the placebo group and 11 in the dutasteride group) ( Table 5) ; only 20 of these were considered as having disease progression (when they were not preceded by another disease progression criterion). There were no surgical interventions, and eight subjects received RT (seven in the placebo group, one in the dutasteride group). Most subjects who required rescue therapy received drug treatment (22 in the placebo group, 10 in the dutasteride group), usually antiandrogens or luteinising hormone-releasing hormone analogues.
Significantly more patients in the dutasteride group than in the placebo group demonstrated a treatment response at month 12 stage at diagnosis (<T2a, T2b-T2c, or >T2c), and last PSA value before radical therapy (<10, 10-20, or >20 ng/ml). 0 1 3 ) 7 7 9 -7 8 7 The incidence of PSA rise was significantly higher in the placebo group compared with the dutasteride group (88% 
Safety assessments
The incidence of AEs, serious AEs, AEs leading to study discontinuation or withdrawal, and fatal AEs were similar between the treatment groups (Table 6 ). No fatal AE was considered to be related to study treatment. The most common AEs (occurring in 5% of patients in either treatment group; data not shown) were nasopharyngitis, urinary incontinence, gynaecomastia, hypertension, and back pain. Breast disorders were more common among subjects in the dutasteride group (n = 10) than in the placebo group (n = 4). Sexual AEs occurred in few subjects and were less common in the dutasteride group than in the placebo group (Table 6) .
Cardiovascular AEs of special interest were reported in four subjects in each treatment group (Table 6) . One cardiac failure AE occurred in the dutasteride group 391 d after treatment initiation, which was considered by the investigator to be unrelated to study treatment and possibly ITT = intention to treat; PSA = prostate-specific antigen; PSADT = prostatespecific antigen doubling time. a Includes ITT subjects who had at least one postbaseline PSA measurement. b Defined as the first time one of the above disease-progression criteria was met during the study. If a subject met more than one disease-progression criterion on the same date, he was counted in each one. c Nine subjects in the placebo group and four in the dutasteride group had bone metastases; four and two of these cases, respectively, were preceded by another disease progression criterion. HT = hormone therapy. a Some of these interventions were preceded by another criterion of disease progression and so would not have counted as a disease progression criterion for a subject.
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related to a concomitant medication (potassium ascorbate). Dutasteride treatment was continued and the event resolved with specific treatment. In contrast, AEs in the cardiac disorders system organ class (SOC) were more common in the dutasteride group (n = 10) than in the placebo group (n = 4). No individual AE in this SOC was reported by more than one subject in either treatment group, with the exception of atrial fibrillation (two subjects in the dutasteride group, one subject in the placebo group).
Discussion
Dutasteride treatment over 2 yr significantly delayed the doubling time for PSA in men with biochemical failure following radical therapy for PCa. Baseline PSA, baseline PSADT, Gleason score and tumour stage at PCa diagnosis, the type of radical therapy received, HT use before screening, and time from radical therapy to screening were all significant predictors of time to PSA doubling. The RR reduction in favour of dutasteride was similar in a model with or without these predictors (70% and 66%, respectively), indicating that subjects in this setting may benefit from dutasteride treatment regardless of baseline characteristics. Secondary efficacy end points reinforced the primary efficacy findings. Dutasteride delayed PCa progression, affecting both PSA-related end points and clinical outcomes (need for rescue therapy and the incidence of bone metastases). The observation that bone metastases developed in fewer patients receiving dutasteride than placebo is of interest; however, the actual number of patients affected was small, and a properly powered, prospective study is needed to confirm this finding. Subgroup analyses according to previous therapy were generally supportive of the results for the overall study population. These analyses should, however, be interpreted with caution given the relatively small sample sizes and the lack of adjustment for multiple end points. Results of other subgroup analyses of interest, including baseline PSADT, were also consistent with those for the overall population.
The primary end point selected for ARTS was time to PSA doubling from start of randomised treatment. Selection of a PSA-related end point is clinically less meaningful than harder end points such as biopsy-confirmed progression in clinical stage or metastases confirmed by bone scan, and may also have resulted in inherent bias in favour of dutasteride given the effect of treatment on PSA levels. Nevertheless, a serial rise in PSA levels after radical therapy typically predates clinically or radiographically detectable metastatic disease by many years [3] , and the population with rising PSA levels represents the second-largest group of patients with PCa [8] . Changes in PSADT may represent a more sensitive end point to detect biological activity than traditional PSA response criteria. For example, in men with a rising PSA level after RP, a median PSADT <10 mo is the most significant predictor for progression to metastatic disease [3] . Similarly, a short PSADT following RT is predictive of progression to metastatic disease [9, 10] .
Dutasteride had predictable and manageable side effects in the study population. The incidence of sexual AEs among men treated with dutasteride was lower than might be expected from the previous safety profile of the drug [11] . However, it is consistent with the impaired sexual function among a substantial proportion of the study population.
Treatment options in men with biochemical progression after radical therapy are limited; therefore, a treatment with limited side effects that delays PSA progression and progression to clinical signs and symptoms could be a useful therapeutic option. Previous studies have investigated agents such as exisulind, rosiglitazone, celecoxib, dietary supplements, and adecatumumab [12] [13] [14] [15] [16] . While some of these studies reported encouraging results [12, 15] , no useful therapies have emerged. The only previous randomised study of a 5a-reductase inhibitor (5-ARI) after RP compared 12 mo of treatment with finasteride and placebo in 120 men with serum PSA levels of 0.6-10.0 ng/ml, no evidence of skeletal metastasis, and no previous ADT [17] . Finasteride delayed the increase in PSA by approximately 9 mo compared with placebo. There were also fewer recurrences in the finasteride group, although the difference compared with the placebo group was not statistically significant. In the present study, dutasteride (a dual 5-ARI) resulted in reductions in both PSA-related progression events and also clinical-related outcomes. Nevertheless, additional data would be helpful in deciding if 5-ARIs could be considered a treatment option in this setting.
A potential concern about using 5-ARIs to treat PCa is that they may shorten the time to development of disease that is resistant to ADT [18] . Despite 5-ARIs being in clinical use for >10 yr and the subject of long-term clinical trials, no such association has yet been reported. However, longerterm follow-up is necessary before this concern can be fully disregarded.
A PSADT of <9 mo has been proposed as a cut-off point conferring an increased risk of PCa death and reduced overall survival [19] [20] [21] . In ARTS, a cut-off of 12 mo was predefined for the efficacy analyses. Among subjects with a 
baseline PSADT of <12 mo, and therefore at theoretically higher risk of PCa-related outcomes, a smaller proportion of the dutasteride group experienced a PSA-doubling event than the placebo group (34% vs 62%). However, based on previous studies [22, 23] , the relatively short follow-up period of ARTS is insufficient to confirm if the impact of dutasteride treatment on PSADT translates into overall or PCa-specific survival; this represents a limitation of the study. Another potential limitation of the study is that investigators and patients were not blinded to PSA test results. Knowledge of PSA level could potentially unblind the study and influence investigators' decisions such as timing of rescue therapy. Revealing PSA values was necessary, however, for investigators to manage their patients and also to explore the impact of the disease and treatment on patient-reported health outcomes (data not shown). Despite this potential limitation, results were consistently in favour of dutasteride across end points, including non-PSA variables such as need for rescue therapy or development of bone metastases.
There was a substantial difference in median follow-up time between the two treatment groups (722 d for the dutasteride group vs 456 d for the placebo group). This is most likely due to the higher withdrawal rate in the placebo group than in the dutasteride group, which, in turn, was driven by withdrawal due to disease progression and investigator/patient decision to withdraw. Withdrawal due to disease progression was based on objective, predefined criteria, indicating a benefit of dutasteride treatment over placebo. Investigator or patient decisions to withdraw may have been more subjective, and potentially influenced by the PSA unblinding.
Conclusions
Dutasteride delayed the biochemical progression of PCa in patients with biochemical failure after radical therapy for clinically localised disease. The safety and tolerability profile of dutasteride in this patient population was generally consistent with previous experience with no new safety signals identified. A larger-scale study with a longer followup period is needed to determine whether delayed biochemical progression translates into improved survival.
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